Human antibodies neutralize enterovirus D68 and protect against infection and paralytic disease

See allHide authors and affiliations

Science Immunology  03 Jul 2020:
Vol. 5, Issue 49, eaba4902
DOI: 10.1126/sciimmunol.aba4902

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

This article has a correction. Please see:

Antibodies inhibit virus-induced paralytic disease

Enterovirus D68 (EV-D68) is a human respiratory virus associated with acute flaccid myelitis, a rare paralytic disease primarily occurring in young children. To develop a potential therapeutic agent for this emerging disease, Vogt et al. screened B cells from participants with past EV-D68 infection for virus-binding antibodies and isolated a series of human monoclonal antibodies (mAbs). One mAb that neutralized virus from all EV-D68 clades tested was shown by cryo–electron microscopy to bind a conformational epitope on the viral capsid surface. This highly cross-reactive mAb also protected immunodeficient mice from EV-D68–induced respiratory and neurological disease when given as prophylaxis or therapy. This research sets the stage for clinical testing of antibody therapy in patients with severe EV-D68 disease when the next virus outbreak occurs.

View Full Text

Stay Connected to Science Immunology